Speaker:

Boris Jordan, Chairman & CEO, Curaleaf

Discussion Points

• Why is Aurora the right target, among NASDAQ listed Canadian LPs

• Why now? why not wait for S3 rescheduling and uplisting

• Comparing cultivation scale and international RTM of the larger Canadian LPs

• Mechanics of an OTC company buying a NASDAQ-listed operator? Plan to keep NASDAQ listing?

• Will regulators in several countries have to approve the deal?

• Plan B for Curaleaf if ACB bid fails • Could this trigger more Canada/US M&A? But more LP greater than MSO than MSO greater than LP

#Curaleaf  ...